Back to Results

Fortress Biotech Inc Pref Series A (FBIOP)

Fortress Biotech Inc Pref Series A (FBIO.P) is a preferred stock listed on NASDAQ and associated with Fortress Biotech, Inc., a biopharmaceutical company based in Bay Harbor Islands, Florida. Fortress Biotech focuses on the development and commercialization of pharmaceutical products across several therapeutic areas, including dermatology, oncology, rare diseases, and infectious disease research. Its portfolio includes marketed products such as Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend, alongside a pipeline of clinical, early-stage, and preclinical candidates. These include programs such as intravenous Tramadol, CUTX-101, UNLOXCYT, Olafertinib, CAEL-101, Triplex, and multiple additional development assets. The company was incorporated in 2006 and adopted its current name in 2015.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-FBIO.P
$18.20
6.1% Upside
Fair
Not available
Not available
Great
0.0%
November 13, 2026
0.8x
0.5x
1.2x
81.71 M
-20.935 M
30.4%
64.3%
1.7
121.7%
Valuation • Fair Value

Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) Fair Value by Valuation Model

Review the available estimates for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P), including Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$18.20

Estimated upside of 6.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Ben Graham Formula Value

$171.45

Classic Ben Graham valuation formula reference.

Comps Fair Value

$18.20

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 4 available valuation references for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

68.466 M

Current operating scale indicator.

Revenue Forecast

78.794 M

Forward revenue estimate.

EBITDA

-24.979 M

Current operating profitability reference.

EBITDA Forecast

-33.5 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-1.94

Intermediate zone that deserves monitoring.

Altman Z-Score

1.7

Lower score that deserves closer risk review.

FCF / Net Income

121.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

52

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) Stock FAQ

Data-supported answers about Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$18.20
Estimated upside 6.1%
Valuation Rating
Undervalued
Estimated upside of 6.1%
Financial Health
Great
Current financial-health read

The current fair value estimate for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) is $18.20. This implies an estimated upside of 6.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 6.1% versus the current market price.

The current financial health read for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) is November 13, 2026.

The latest available data indicates no current dividend yield for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P).

The current P/E ratio listed for Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) is 0.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Fortress Biotech Inc Pref Series A is 81.71 M.

The current enterprise value listed for Fortress Biotech Inc Pref Series A is -20.935 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Fortress Biotech Inc Pref Series A is NASDAQ-FBIO.P, and the stock is listed on NASDAQ.

Fortress Biotech Inc Pref Series A (NASDAQ-FBIO.P) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Fortress Biotech Inc Pref Series A is 30.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Fortress Biotech Inc Pref Series A is 64.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B